Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer

Journal of Clinical Oncology

Volumn 20, Issue 16, 2002, Pages 3522-3532

  Rizvi, Naiyer A ^a   Marshall, John L ^a   Ness, Elizabeth ^a   Hawkins, Michael J ^a   Kessler, Craig ^a   Jacobs, Helena ^a   Brenckman, Wayne D ^a   Lee, Jin S ^a   Petros, William ^a   Hong, Waun K ^a   Kurie, Jonathan M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3,5 BIS(TRIMETHYLSILYL)BENZAMIDE]BENZOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID; TAC 101; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZOATES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; THROMBOEMBOLISM; TRIMETHYLSILYL COMPOUNDS;

EID: 0037102143     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.02.090     Document Type: Article

References (26)

1. The retinoid signaling pathway: Molecular and genetic analyses
2. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells
3. 13-cis-retinoic acid in the treatment of oral leukoplakia
4. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck
5. Acute promyelocytic leukemia
6. The retinoid receptors
7. A decade of molecular biology of retinoic acid receptors
8. 9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor
9. Retinobenzoic acids: 5-Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL- 60
10. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells
11. Effect of 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L 5 carcinoma cells
12. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span
13. Anticancer effect of 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity
14. The induction of apoptosis and inhibition of AP-1 activity by TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid) may result in life prolonging effect in animals bearing metastasizing cancer
15. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101
16. Phase I study of 13-cis-retinoic acid toxicity
17. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors
18. Initial clinical trial of a selective retinoid X receptor ligand, LGD 1069
19. A phase I study of LGD 1069 in adults with advanced cancer
20. Lack of involvement of retinoic acid receptor alpha in retinoid-induced skin irritation in hairless mice
21. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer
22. Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids
23. A novel retinoic acid receptor-selective retinoid, ALRT 1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice
24. Differential responses of normal, premalignant, and malignant human bronchial epithelial cells to receptor-selective retinoids
25. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells
26. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells